dalfopristin

component of RP-59500; structure in first source

Also Known As:

26-(2-diethylaminoethyl)sulfonylpristamycin IIB; RP 54476; RP-54476; (3R,4R,5E,10E,12E,14S,26R,26aS)-26-((2-(diethylamino)ethyl)sulfonyl)-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo(2,1-c)(1,8,4,19)dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone

Networked: 20 relevant articles (0 outcomes, 0 trials/studies)

Drug Context: Research Results

Experts

1.	Courvalin, Patrice: 2 articles (12/2014 - 08/2003)
2.	Dalgic, Nazan: 1 article (10/2019)
3.	Şahin, Ayşe: 1 article (10/2019)
4.	He, Wenbin: 1 article (01/2017)
5.	Kates, Stephen L: 1 article (01/2017)
6.	Li, Zhengdao: 1 article (01/2017)
7.	Liu, Yi: 1 article (01/2017)
8.	Peng, Jiachen: 1 article (01/2017)
9.	Ren, Youliang: 1 article (01/2017)
10.	Schwarz, Edward M: 1 article (01/2017)

Related Diseases

1.	Infections 01/01/2004 - "/dalfopristin is administered at 7.5 mg/kg every 8-12 hours, depending upon the severity of infection. " 12/01/2000 - "Quinipristin-dalfopristin and linezolid are 2 new approved antimicrobials for the treatment of recalcitrant infections caused byVRE. " 05/01/1997 - "This result emphasizes the importance of the constant presence of dalfopristin at the site of infection to ensure synergism with quinupristin." 08/01/1999 - "New antibiotics for gram positive infections: linezolid and combination quinapristin/dalfopristin." 10/01/2000 - "Rhône-Poulenc Rorer (RPR) developed Synercid (RP-59500), an injectable synergistic combination of quinupristin and dalfopristin as a treatment for a variety of infections caused by Gram-positive anaerobic bacteria. "
2.	Endocarditis 05/01/1998 - "Staphylococcus epidermidis endocarditis treated with RP 59500 (quinapristin/dalfopristin)." 05/01/1997 - "faecium on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis may be related to the reduced diffusion of dalfopristin compared with that of quinupristin into cardiac vegetations that we previously reported. " 03/01/1994 - "We evaluated the in vivo activity and the diffusion of radiolabelled RP 57669 (RPI) and RP 54476 (RPII), the two components of the injectable streptogramin RP 59500, alone or in combination, in aortic vegetations from experimental endocarditis in rabbits. "
3.	Sepsis (Septicemia) 11/02/2023 - "Several other targeted drugs were also identified in other types of sepsis, including nystatin targeting C1QA in Neisseria sepsis and dalfopristin targeting CTSD in Streptococcus viridans sepsis. "
4.	Bacteremia 12/09/1996 - "Four of the 6 bacteremia cases were central-line related and resolved with line removal alone; 1 was treated with a combination product of quinupristin and dalfopristin (Synercid) and 1 had persistent bacteremia in the presence of a ventriculoperitoneal shunt. "
5.	Pyelonephritis 11/01/2010 - "Potential parenteral agents for the treatment of pyelonephritis and complicated UTIs caused by MDR-Enterococcus include daptomycin, linezolid, and quinipristin-dalfopristin. "

Related Drugs and Biologics

1.	quinupristin
2.	quinupristin-dalfopristin (Synercid)
3.	Streptogramins
4.	Linezolid (Zyvox)
5.	Vancomycin
6.	Anti-Bacterial Agents (Antibiotics)
7.	Daptomycin
8.	Tigecycline (Tygacil)
9.	Rifampin (Rifampicin)
10.	Piperacillin

Related Therapies and Procedures

1.	Injections
2.	Ventriculoperitoneal Shunt
3.	Duration of Therapy